THE DUBERSTEIN GROUP INC. for PHRMA INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Tax extenders - HR 2029, Consolidated Appropriations Act, 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Medicare/Medicaid MMM
Medicare Part B issues - HR 2029, Consolidated Appropriations Act, 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Debt limit and continuing resolution and possible healthcare related pay-fors - HR 719, Continuing Appropriations Act, 2016; HR 1314, Bipartisan Budget Act of 2015. Possible amendments regarding healthcare pharmaceuticals - HR 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Health Issues HCR
21st Century Cures - HR 6, 21st Century Cures Act. Healthcare issues included in reconciliation - HR 3762, Restoring Americans' Healthcare Freedom Reconciliation Act of 2015. Healthcare issues included in Omnibus Appropriations bill - HR 2029, Consolidated Appropriations Act, 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KENNETH DUBERSTEIN | — |
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.